Cargando…
Covid-19 in Philadelphia-negative myeloproliferative neoplasms: a GIMEMA survey on incidence, clinical management and vaccine
| Autores principales: | , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9375079/ https://www.ncbi.nlm.nih.gov/pubmed/35963940 http://dx.doi.org/10.1038/s41375-022-01675-1 |
| _version_ | 1784767883119689728 |
|---|---|
| author | Breccia, M. Piciocchi, A. Messina, M. Soddu, S. De Stefano, V. Bellini, M. Iurlo, A. Martino, B. Siragusa, S. Albano, F. Mora, B. Fazi, P. Vignetti, M. Guglielmelli, P. Palandri, F. |
| author_facet | Breccia, M. Piciocchi, A. Messina, M. Soddu, S. De Stefano, V. Bellini, M. Iurlo, A. Martino, B. Siragusa, S. Albano, F. Mora, B. Fazi, P. Vignetti, M. Guglielmelli, P. Palandri, F. |
| author_sort | Breccia, M. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9375079 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Nature Publishing Group UK |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-93750792022-08-15 Covid-19 in Philadelphia-negative myeloproliferative neoplasms: a GIMEMA survey on incidence, clinical management and vaccine Breccia, M. Piciocchi, A. Messina, M. Soddu, S. De Stefano, V. Bellini, M. Iurlo, A. Martino, B. Siragusa, S. Albano, F. Mora, B. Fazi, P. Vignetti, M. Guglielmelli, P. Palandri, F. Leukemia Correspondence Nature Publishing Group UK 2022-08-13 2022 /pmc/articles/PMC9375079/ /pubmed/35963940 http://dx.doi.org/10.1038/s41375-022-01675-1 Text en © The Author(s), under exclusive licence to Springer Nature Limited 2022 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
| spellingShingle | Correspondence Breccia, M. Piciocchi, A. Messina, M. Soddu, S. De Stefano, V. Bellini, M. Iurlo, A. Martino, B. Siragusa, S. Albano, F. Mora, B. Fazi, P. Vignetti, M. Guglielmelli, P. Palandri, F. Covid-19 in Philadelphia-negative myeloproliferative neoplasms: a GIMEMA survey on incidence, clinical management and vaccine |
| title | Covid-19 in Philadelphia-negative myeloproliferative neoplasms: a GIMEMA survey on incidence, clinical management and vaccine |
| title_full | Covid-19 in Philadelphia-negative myeloproliferative neoplasms: a GIMEMA survey on incidence, clinical management and vaccine |
| title_fullStr | Covid-19 in Philadelphia-negative myeloproliferative neoplasms: a GIMEMA survey on incidence, clinical management and vaccine |
| title_full_unstemmed | Covid-19 in Philadelphia-negative myeloproliferative neoplasms: a GIMEMA survey on incidence, clinical management and vaccine |
| title_short | Covid-19 in Philadelphia-negative myeloproliferative neoplasms: a GIMEMA survey on incidence, clinical management and vaccine |
| title_sort | covid-19 in philadelphia-negative myeloproliferative neoplasms: a gimema survey on incidence, clinical management and vaccine |
| topic | Correspondence |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9375079/ https://www.ncbi.nlm.nih.gov/pubmed/35963940 http://dx.doi.org/10.1038/s41375-022-01675-1 |
| work_keys_str_mv | AT brecciam covid19inphiladelphianegativemyeloproliferativeneoplasmsagimemasurveyonincidenceclinicalmanagementandvaccine AT piciocchia covid19inphiladelphianegativemyeloproliferativeneoplasmsagimemasurveyonincidenceclinicalmanagementandvaccine AT messinam covid19inphiladelphianegativemyeloproliferativeneoplasmsagimemasurveyonincidenceclinicalmanagementandvaccine AT soddus covid19inphiladelphianegativemyeloproliferativeneoplasmsagimemasurveyonincidenceclinicalmanagementandvaccine AT destefanov covid19inphiladelphianegativemyeloproliferativeneoplasmsagimemasurveyonincidenceclinicalmanagementandvaccine AT bellinim covid19inphiladelphianegativemyeloproliferativeneoplasmsagimemasurveyonincidenceclinicalmanagementandvaccine AT iurloa covid19inphiladelphianegativemyeloproliferativeneoplasmsagimemasurveyonincidenceclinicalmanagementandvaccine AT martinob covid19inphiladelphianegativemyeloproliferativeneoplasmsagimemasurveyonincidenceclinicalmanagementandvaccine AT siragusas covid19inphiladelphianegativemyeloproliferativeneoplasmsagimemasurveyonincidenceclinicalmanagementandvaccine AT albanof covid19inphiladelphianegativemyeloproliferativeneoplasmsagimemasurveyonincidenceclinicalmanagementandvaccine AT morab covid19inphiladelphianegativemyeloproliferativeneoplasmsagimemasurveyonincidenceclinicalmanagementandvaccine AT fazip covid19inphiladelphianegativemyeloproliferativeneoplasmsagimemasurveyonincidenceclinicalmanagementandvaccine AT vignettim covid19inphiladelphianegativemyeloproliferativeneoplasmsagimemasurveyonincidenceclinicalmanagementandvaccine AT guglielmellip covid19inphiladelphianegativemyeloproliferativeneoplasmsagimemasurveyonincidenceclinicalmanagementandvaccine AT palandrif covid19inphiladelphianegativemyeloproliferativeneoplasmsagimemasurveyonincidenceclinicalmanagementandvaccine |